Keytruda Revenue 2024. Keytruda sales grew 19% to $25.0 billion; The pharmaceutical segment contributed $53.58 billion last year, up 3 percent from.
Revenue and profit beat expectations. The company reported $5.3 billion in sales of keytruda, compared with analyst estimates of $4.9 billion.
Revenue And Profit Beat Expectations.
Meacham’s analysis suggests that while merck is on a stable path to maintain revenue levels comparable to 2023 by 2033, there is still a need for.
Keytruda Sales Grew 19% To $25.0 Billion;
Excluding the impact of foreign exchange, sales grew 21% gardasil/gardasil 9 sales grew 29% to $8.9 billion;
Patent Expires In 2028, Which.
Images References :
Keytruda Pivotal For Merck's Revenues, Diversification Strategy Continues.
Keytruda sales for the quarter rose 20% to $6.9 billion, ahead of the $6.7 billion average foreseen by analysts.
Revenue And Profit Beat Expectations.
The revenue total beat wall street’s consensus estimate of $59.98 billion.
Taken Together, Earnings Per Share Were $2.07, Which Includes A $0.26 Negative Impact From The Charge Related To Harpoon.